Pharmacogenetics

For a personalized treatment

View study
For a personalized treatment For a personalized treatment

CLINICAL EXPERIENCE AND
KNOWLEDGE MANAGEMENT

Clinical experience

Integrated by clinicians and pharmacists specialized in the field of clinical pharmacology and physicians specialized in internal medicine, cardiology, neurology, clinical geneticists, biologists and bioinformaticians

Knowledge Management

Expert detailed curation of Scientific Literature and recommendations of the main clinical pharmacogenetics guidelines

Lastest technologies

Deep sequencing NGS approach with an in-house designed panel. Allows for the study of highly polymorphic genes and structural variants (CNVs)

Pharmacogenetic study

Pharmacogenetics Global Panel

[85 DRUGS, 17 GENES AND 935 GENETICS REGIONS]

The pharmacogenetics global panel analyzes genetic-based variation in response to different drugs within a single panel. The study includes all drugs and genetic variants included in the recommendations of the main clinical pharmacogenetics guidelines.

Results are communicated via a report aimed at healthcare professionals. The report contains dosing strategies recommended in the main published clinical practice guidelines in the field of pharmacogenetics and in summaries of product characteristics of the different drugs, as well as a color-coded priority ranking for easy interpretation and application.

The global pharmaHIC panel provides information on treatment individualization for 85 drugs, 17 genes, and 935 genetic regions.

DOWNLOAD & FILL OUT
BOTH DOCUMENTS

STUDIED DRUGS:

Central Nervous System

Antidepressants

Selective serotonin reuptake inhibitors
(SSRIs): citalopram, escitalopram, fluvoxamine, paroxetine, sertraline.
Selective serotonin and noradrenalin reuptake inhibitor (SNRIs): venlafaxine, desvenlafaxine, duloxetine.
Tricyclic antidepressants (TCA): amitriptyline, clomipramine, doxepin, imipramine, nortriptyline, trimipramine.
Other antidepressants: mirtazapine, moclobemide, vortioxetine, nefazodone.

Antipsychotics

First generation antipsychotics (FGA): haloperidol, zuclopenthixol, pimozide, perphenazine.
Second generation antipsychotics (SGA): aripiprazole, clozapine, olanzapine, risperidone.

Antiepileptics: phenytoine, carbamazepine, oxcarbazepine.

Centrally acting sympathomimetics: atomoxetine.

Benzodiazepines: diazepam, clobazam, brivaracetam.

Digestive System

Antiemetic 5-HT3 antagonists: ondansetron, tropisetron.

Gastric protectors (Proton pump inhibitors): esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole.

Analgesics

Codeine, tramadol, oxyodone.

Antineoplastic and immunosuppressive agents

Fluoropyrimidines: 5-fluorouracil, capecitabine.

Topoisomerase inhibitors: irinotecan.

Hormone therapy: tamoxifen.

Thiopurines: azathioprine, mercaptopurine, thioguanine.

Calcineurin inhibitors: tacrolimus.

Anthracyclines: doxorubicin, daunorubicin.

Platins: cisplatin.

Cardiovascular system

Antiplatelet agents: clopidogrel, ticagrelor.

Oral anticoagulants: acenocoumarol, warfarin, apixaban, rivaroxaban.

Hypolipidemic agents: atorvastatin, fluvastatin, lovastatin, pitavastatin, simvastatin, rosuvastatin, pravastatin.

Beta blockers: bisoprolol, carvedilol, metoprolol, nebivolol, propranolol.

Antiarrhythmics: amiodarone, dronedarone, flecainide, propafenone.

Infectious diseases

Antifungal agents: voriconazole.

Antiviral agents-HCV: peginterferon alfa-2A, peginterferon alfa-2B, ribavirin.

Antiretroviral agents-HIV: abacavir, atazanavir.

Endocrine system and metabolism

Oral antidiabetics

Sulfonylureas: gliclazide, glimepiride, glibenclamide, tolbutamide.

Hypouricemic agents: allopurinol, rasburicase.

Contraceptives:: estrogen oral contraceptives.

PRIORITY GENES FOR STUDY:

CYP1A2 (16 alleles, 14 regions) CYP2C9 (13 alleles, 14 regions) CYP3A4 (22 alleles, 20 regions)
F5 (1 allele, 1 region) HLA-A (1 allele, 1 region) IFNL3 (1 allele, 1 region)
SLC28A3 (1 allele, 1 region) TPMT (12 alleles, 7 regions) UGT1A6 (6 alleles, 4 regions)
CYP2C19 (15 alleles, 15 regions) CYP2D6 (28 alleles, 24 regions, CNVs studies) DPYD (12 alleles, 10 regions)
G6PD (212 alleles, 173 regions) HLA-B (2932 alleles, 627 regions) RARG (1 allele, 1 regions)
SLCO1B1 (19 alleles, 15 regions) UGT1A1 (8 alleles, 6 regions) VKORC1 (1 allele, 1 region)

TAT [turnaround time]: 5 weeks.
Sources of information and main clinical guidelines: Clinical Pharmacogenetics Implementation Consortium (CPIC) [40 drugs] | Royal Dutch Association for the Advancement of Pharmacy – Pharmacogenetics Working Group (DPWG) [54 drugs] | Canadian Pharmacogenomics Network for Drug Safety (CPNDS) [7 drugs] | Guidelines by other scientific societies: Groupe de Pharmacologie Clinique Oncologique (GPCO-Unicancer), French Réseau National de Pharmacogénétique Hospitalière (RNPGx), American College of Rheumatology (ACR) [2 drugs]
CLIA ID Number: 99D2153048
UNE-EN ISO 9001 | N.º ES093037-2
UNE-EN ISO 14001 | N.º ES093036-2

How to order

Download & fill out

Please cover as many fields as possible in both documents

Obtain sample

3 sample types: saliva, peripheral blood or genomic DNA

Pack the sample

Please pack the sample in a way to prevent leakage

Send the sample & the request

Please schedule the delivery for Mon–Thur: 8am – 5pm

Result: the report

Via HIC Client Portal / Certified email

Edificio O Fortín, As Xubias s/n.
C.P.15006. A Coruña.
Spain

We can process 3 different sample types:

Peripheral blood

(3 to 5 ml in EDTA tubes)

Genomic DNA

NGS > 5-10µg | SANGER > 1µg.
(A260/280 = 1.8-1.9)

Saliva

Order our kit

The sample collection tube must be placed inside a secondary package of the appropriate size for the number of samples shipped. Sufficient absorbent material should be included to absorb all the contents of the primary recipient in case of leakage.

Both containers will preferably be placed inside a rigid box for blood and tissue samples.

THE STUDY MUST BE REQUESTED BY A HEALTHCARE PROFESSIONAL (PHARMACIST OR PHYSICIAN)

PLEASE CONTACT YOUR PHARMACY OR MEDICAL CENTER FOR MORE INFORMATION

see list of centers